The time for a Sarepta Therapeutics (SRPT) takeover is 'ripe' states analyst

Oppenheimer analyst Hartaj Singh said in a note Friday that Sarepta Therapeutics (NASDAQ: SRPT) is "ripe" for a takeover.

Singh, who has an Outperform rating and a $150 price target on the stock, explained that while the M&A Buy thesis for Sarepta has been explained well, they believe the timing might be "more ripe currently."

Sarepta Therapeutics shares are down 0.4% at the time of writing. However, they have climbed 27% so far in 2022.

Oppenheimer upgraded Sarepta in December last year, stating it had a "best-in-class rh74 AAV capsid."

In today's note, Singh wrote: "The best-in-class safety profile for SRPT's rh74 AAV vector is bolstered by the company's leading manufacturing expertise in this area; possibly creating a significant moat around the muscular dystrophy programs. The LGMD programs and the RNA-based PPMO programs are underappreciated. We stay bullish."

"The optics for a SRPT takeout are easy, in our view: (1) a leader in gene therapy, (2) a leader in muscular dystrophies (DMD, LGMDs), (3) a fairly diverse pipeline with RNA-targeted therapies and gene editing approaches also, and (4) a strong financial backdrop to achieve its objective to be a leader in genetic medicines in rare diseases. We add some nuance to these views," he added.

By Sam Boughedda

You May Also Be Interested In

• BTIG sees a 'choppy' H1 followed by a strong H2 for Consumer Retail and Lifestyle Brands firms
• Fujitsu General Limited (6755:JP) (FGELF) PT Raised to JPY3,400 at Nomura/Instinet
• Biden expected to call for 400% increase in buyback tax